Overcoming adherence barriers in oral anticancer medications
Over the past decade, treatment in a variety of cancers, particularly breast cancer, chronic myelogenous leukemia, and non-small cell lung cancer, has switched from intermittent intravenous therapy to self-administered targeted oral anticancer medications (OAMs). There are more than 50 of…